Welcome to our dedicated page for Oculis Holding news (Ticker: OCS), a resource for investors and traders seeking the latest updates and insights on Oculis Holding stock.
Oculis Holding AG reports news on a late-stage ophthalmology and neuro-ophthalmology pipeline focused on eye and optic-nerve disorders with unmet medical need. Company updates commonly cover OCS-01 eye drops for diabetic macular edema, Privosegtor for optic neuritis and other optic neuropathies, and Licaminlimab, a topical anti-TNFα candidate being developed for dry eye disease with a genotype-based approach.
Recurring developments include clinical-program updates, FDA and EMA regulatory interactions, scientific meeting presentations, pipeline reviews, financial results, capital-market communications, annual general meeting materials, and notifications of managerial transactions. Oculis is a Swiss biopharmaceutical company with ordinary shares traded on Nasdaq and Nasdaq Iceland under OCS.
Oculis (Nasdaq: OCS) announced management participation in multiple investor conferences in November 2025, including Guggenheim (Nov 10-12), Stifel (Nov 11-13), LifeSci Capital & Sofinnova (Nov 17) and ICR Healthcare (Nov 17).
Key program items: Privosegtor advanced into registrational trials for acute optic neuritis and NAION after a positive FDA meeting; OCS-01 topline results for diabetic macular edema expected in Q2 2026; and Licaminlimab PREDICT-1 registrational trial in DED anticipated soon as a genotype-based program. CEO Riad Sherif will give fireside chats on Nov 11 (2:30 pm ET) and Nov 12 (2:00 pm ET); management will be available for one-on-one meetings and webcasts will be posted to the Events & Presentation page.
Oculis (Nasdaq: OCS) and EURETINA awarded the Ramin Tadayoni Award 2025 to Dr. Prithvi Ramtohul for retina research.
The award, established in 2024 to honor Professor Ramin Tadayoni, supports postgraduate retinal research and recognizes Dr. Ramtohul's work on retinal imaging, including studies of retinal ganglion cell plasticity and multimodal imaging findings such as BALAD and ASHH. Oculis reiterated its collaboration with EURETINA and commitment to advancing retinal science through this annual prize.
Oculis (Nasdaq: OCS) priced an offering of 5,432,098 ordinary shares at $20.25 per share for aggregate gross proceeds of $110 million, and granted underwriters a 30-day option to buy up to 703,703 additional shares. The Offerings split into an underwritten offering of 4,691,358 shares and a registered direct offering of 740,740 shares, expected to close on or about November 3, 2025.
Of the shares, 2,635,801 are new issue from the company’s capital band and 3,500,000 are treasury shares; issuance will raise authorized registered shares to 57,169,475. Net proceeds are intended to accelerate development of Privosegtor for acute optic neuritis and NAION, and for working capital and general corporate purposes.
Oculis (NYSE:OCS) disclosed two notifications dated Oct 14, 2025 showing a director exercised vested stock options and then sold the resulting ordinary shares.
The filings indicate the transactions were executed under a 10b5-1 trading plan in accordance with Rule 10b5-1(c)(1) of the Securities Exchange Act of 1934. Attachments reference notifications for C. Ackermann covering the option exercise and subsequent share sale.
Oculis (Nasdaq: OCS) will highlight its late-stage ophthalmology pipeline at Eyecelerator and the AAO Annual Meeting in Orlando, Oct 16–20, 2025.
Key updates include: Privosegtor advancing into registrational trials for acute optic neuritis and non-arteritic anterior ischemic optic neuropathy after a positive meeting with the FDA; OCS-01 (DIAMOND Phase 3) with expected topline readouts in Q2 2026; and the planned PREDICT-1 registrational trial of Licaminlimab using a genotype-based approach anticipated to start in Q4 2025. CEO Riad Sherif will present at Eyecelerator on Oct 16, 2025; Oculis will also participate in Innovate Retina, SAIVO and COPhy events and staff booth 1353 during AAO.
Oculis (OCS) announced a notification of a manager's transaction dated October 8, 2025. The disclosure states that restricted stock units (RSUs) previously granted to director Riad Sherif have vested and been settled in October 2025. The notice includes an attachment with the formal managers' transaction notification.
Oculis (Nasdaq: OCS) announced a positive meeting with the FDA and is launching the PIONEER program to advance Privosegtor into registrational trials for acute optic neuritis (AON) and non-arteritic anterior ischemic optic neuropathy (NAION).
The company plans three pivotal studies: PIONEER-1 (Q4 2025), PIONEER-2 (1H 2026), and PIONEER-3 (mid-2026). Primary endpoint: low-contrast visual acuity (LCVA) at 3 months, with dosing/enrollment mirroring the positive Phase 2 ACUITY trial. Oculis reported preliminary cash, cash equivalents and short-term investments of ~$182 million, with runway expected into 2H 2027. Full Q3 2025 results are planned for November 10, 2025.
Oculis (NASDAQ:OCS) has announced that a Person Discharging Managerial Responsibilities (PDMR) has executed trades in accordance with a pre-established Rule 10b5-1 trading plan. The transactions were conducted under the Securities Exchange Act of 1934 guidelines, demonstrating compliance with regulatory requirements for insider trading.
Oculis (NASDAQ: OCS) announced upcoming presentation of positive Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis at ECTRIMS 2025 Congress. The trial demonstrated clinically meaningful improvements in vision with 18 letters at 3 months, preservation of retinal structure, and a favorable safety profile.
The presentation, scheduled for September 24, 2025, will be delivered by Dr. Céline Louapre from Pitié-Salpêtrière Hospital. The study showed promising neuroprotective effects, including preservation of retinal ganglion cells and significant improvements in low contrast visual acuity, highlighting potential applications in multiple sclerosis relapses and other neuro-ophthalmic conditions.
Oculis (NASDAQ:OCS) has announced the vesting and settlement of Restricted Stock Units (RSUs) for several company directors. The notifications concern RSU settlements for directors Anthony Rosenberg, Christina Ackermann, Arshad Khanani, and Robert Warner.